article thumbnail

$2 billion mRNA-based oncology therapy market anticipated by 2029

European Pharmaceutical Review

The global mRNA-based oncology therapy market is expected to reach $2 billion by 2029, according to GlobalData. BioNTech is anticipated to lead the market with a predicted $885 million in sales, and a 44.6 percent share by 2029, the research has shown. percent of the total mRNA therapy market by 2029.

Marketing 110
article thumbnail

The future of pain medication: are cannabinoids the solution to the opioid epidemic?

Pharmaceutical Technology

In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. A promising example includes Vertex Pharmaceuticals’s VX-548, a sodium channel subunit blocker. Six cannabinoids have recently completed or are undergoing Phase II trials.

Medical 143
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Seeking Ofev successor, Boehringer takes PDE4B drug into phase 3

pharmaphorum

There are more than 200 lung disorders that can lead to pulmonary fibrosis. Ofev is, however, heading for patent expiry in 2029, and Boehringer is looking to BI 1015550 to maintain the franchise beyond that date, and also to improve the treatment of IPF, which remains incurable.

article thumbnail

Biopharma sees strong Q2 2023 market cap growth

European Pharmaceutical Review

For 20 of the leading biopharmaceutical companies, the second quarter (Q2) of 2023 has brought an aggregate market capitalisation growth of 2.3 billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted. trillion in the Q1 of 2023 to $3.56

article thumbnail

Novo Nordisk blockbuster Ozempic boasts 23% sales surge in 2023

Pharmaceutical Technology

Novo Nordisk’s leading drug Ozempic (semaglutide) is forecast to demonstrate a sales growth of 23% in 2023. In 2022, US sales of Ozempic contributed to 65% of global sales; this is expected to continue, with the US market forecast to continue capturing the majority of sales, generating $71bn between 2023–2029.

Sales 52
article thumbnail

Market outlook to 2032: future trends across the seven major markets

European Pharmaceutical Review

GlobalData’s Analyst covering Neurology and Ophthalmology, Thomas Parker, MPharmacol, predicted that Belsomra would lead the market by 2023. In the US in 2029 and in Japan in 2031, Belsomra is set to lose market exclusivity. billion by 2023, driven by the launch of Merck’s Belsomra and Eisai’s lemborexant (E-2006).

article thumbnail

Emerging Trends in Orthopedic Medical Device Industry

Medico Reach

However, this can lead to several issues, such as: Implantation resistance due to reactionary metabolism Allergic reactions to the nickel component found in stainless steel composites Widespread bone destruction due to immunological responses to cobalt particles. billion by 2029. The US-based Enovis is leading this new development.

Medical 98